FDC Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2p3eslug2iddmlezy0tpkzxi.pdf

Key Takeaways


Domestic Performance & Brand Dynamics

Mayank Tikkha: "It is not a 100% prescription driven market of energy drinks. That is the reason why we have lost but the domain at which we operate that is the doctor fraternity and the chemist business probably we have not lost any market share but to be fair we have given you the market dynamics overall."

Export & US Strategy

Ameya Chandavarkar: "We have not categorically said that we don't intend to be there ourselves so I'm not sure where you're getting that information from. We are still open to that possibility. However right now we are happy partnering and it's been a very lucrative market for us, particularly from the bottom-line perspective."

Margin & Cost Structure

Sanjay Jain: "You are all aware there are input costs are going up everywhere. We are not sure how it will pan out in the next 12 month of period. We have to wait and watch so that we can give you further guidance on that."

Portfolio Reshaping & New Launches

Mayank Tikkha: "Very difficult to say, very early days because our top brands already touching Rs. 300 crores what we share. Now this molecule or maybe this product, doesn't have that kind of potential in the market as of now; as of now we are talking about."

Capital Allocation & Infrastructure


Guidance & Commitments

CommitmentSpecificsTimeline
Export baseMarch '21 export number can be taken as a base for future growthOngoing
CapexRs. 120 cr planned; similar amount likely in FY24; total plan >Rs. 200 crFY23–FY24
Office building~Rs. 200 cr construction cost, ~1 lakh sq ft, 2–2.5 years to complete2–2.5 years
South Africa turnaroundNew hire in place; will take at least 2–3 years to turn the business around2–3 years
International business growthExpect meaningful growth over the next 3–5 years3–5 years
Domestic growth driversFive focus categories (antibiotics, Electral-Enerzal, nutraceuticals, dermatology, cardio-diabeto) to drive growth over next 2–3 to 5 years2–5 years
IPM outperformanceInternally confident of growing ahead of IPM in FY23-24, but cannot guarantee any number because the post-COVID market is behaving in a very uncertain mannerFY23–FY24, conditional on market stability

Key Metrics

MetricQ4 FY22
Revenue growth9% YoY; 15% for FY22 year-end
Domestic formulation growth18% YoY; 31% for FY22 year-end
Export formulation growth-15% YoY; -35% for FY22 year-end
Export formulation revenue₹47 cr, up from ₹37 cr in Q3 FY22
EBITDA margin5% for Q4 FY22; 16% for FY22 year-end
Employee cost22% of revenue, stable
Gross margin impact: COVID inventory provision₹11.70 cr one-off provision, ~2% impact on gross margin
Gross margin impact: raw material inflation1% to 1.5% on a quarter and YoY basis
India portfolio weighted average price increase5% to 6% (₹70–80 cr annualized)
NLEM price increase10.7%
Non-NLEM price increase10% wherever possible
Logistic costs as a percentage of revenue3.5% in FY22, up from 2.5% in FY21
CAPEX plan for FY23₹120 cr; similar expected for FY24, total plan over ₹200 cr
Cash balance~₹750 cr post-buyback (₹850 cr before buyback of ~₹170 cr)
Medical representatives3,242; total field force increased by ~500 in FY22
R&D expenditure2% of revenue
Favipiravir revenue~₹18 cr in FY22
US share of export formulation revenue50% in Q4 FY22